Loading...
XJPX
4577
Market cap251mUSD
Dec 05, Last price  
1,301.00JPY
1D
-0.69%
1Q
5.43%
Jan 2017
-36.51%
IPO
0.85%
Name

Daito Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4577 chart
P/E
20.45
P/S
0.77
EPS
63.63
Div Yield, %
5.00%
Shrs. gr., 5y
16.60%
Rev. gr., 5y
2.39%
Revenues
50.64b
+7.99%
21,460,675,00022,679,543,00025,218,380,00027,149,438,00028,959,211,00031,202,240,00034,062,366,00036,331,198,00037,973,361,00039,883,625,00041,135,053,00044,997,108,00048,709,171,00043,464,000,00045,101,000,00046,895,000,00050,643,000,000
Net income
1.91b
-42.09%
692,964,000752,385,000990,619,0001,389,140,0001,786,636,0001,811,396,0002,246,122,0002,566,419,0002,656,281,0003,041,941,0003,513,028,0003,944,714,0004,246,000,0004,668,000,0003,600,000,0003,295,000,0001,908,000,000
CFO
5.90b
+13.80%
1,020,926,0002,167,203,0002,829,083,0003,342,888,0002,541,424,0002,744,650,0003,739,312,0002,948,858,0005,069,743,0005,465,342,0006,888,157,0004,306,265,0005,182,527,0004,370,000,0004,155,000,0005,182,000,0005,897,000,000
Dividend
Nov 27, 202520 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
URL
https://www.daitonet.co.jp/
IPO date
Mar 24, 2010
Employees
1,011
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT